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An rearrangement was detected by FISH analysis using a breakapart probe specific 
for the  locus (Vysis LSI ALK dualcolor, breakapart rearrangement probe; Abbott 
Molecular, Abbott Park, IL, USA) in formalinfixed, paraffinembedded (FFPE) tumor tissue 
samples. FISHpositive samples were defined as those with more than 15% of tumor cells 




Total RNA was extracted from the FFPE cell blocks using the PureLink™ FFPE Total 
RNA Isolation Kit (Invitrogen, Carlsbad, CA, USA) with the following protocol 
modifications. The resulting RNA was eluted with 50 8L of elution buffer. The concentration 
and purity of the extracted RNA were determined by means of a Nanodrop (Thermo Fisher. 
USA). The extracted RNA was stored at −80°C until use. We used 250 ng of total RNA to 
generate cDNA using the Super Script VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, 
USA). 





The  fusion RNA was detected using PANAqPCR™  Fusion Gene 
Detection Screening and Genotyping Kit (Panagene, Daejeon, Korea), which tests for 28 
types of known  rearrangements including E6;A19, E6;A20 (variant 3a), E6ins33;A20 
(variant 3b, 3 subtypes), E6;ins18A20, E13;A20 (variant 1, 5 subtypes), E13;ins69A20 
(variant 6, 2 subtypes), E20;A20 (variant 2, 2 subtypes), E20;ins18A20 (2 subtypes), 
E14ins11;del49A20 (variant 4), E14;del12A20 (variant 7), E14;del36A20, E14ins2;ins56A20, 
E2;A20 (variant 5a), E2;ins117A20 (variant 5b), E17;ins30A20 (variant 8a), 
E17ins61;ins34A20 (variant 8b), E17ins65;A20, E17;ins68A20, and E17del58;ins39A20.  
 translocationpositive samples were further genotyped to detect the presence of 
any of these 12 variants: E6;A20 (variant 3a), E6ins33;A20 (variant 3b), E13;A20 (variant 1), 
E13;ins69A20 (variant 6), E20;A20 (variant 2), E14ins2;ins56A20, E14ins11;del49A20 
(variant 4), E14;del12A20 (variant 7), E2;A20 (variant 5a), E2;ins117A20 (variant 5b), 
E17;ins30A20 (variant 8a), and E17ins61;ins34A20 (variant 8b). The PCR was conducted 
under the following conditions: 2 min at 50°C; 15 min at 95°C; five cycles of 10 s at 95°C 
and 30 s at 58°C; and 45 cycles of 10 s at 95°C, 30 s at 58°C, and 15 s at 72°C. A positive 
result for  was defined as a threshold cycle (CT) value <40, and the internal 





The  and cDNAs were cloned by PCR from human cDNA (Clontech, Mountain 
View, CA, USA). V1, V2, V3a, and V5a were constructed by ligating 
cDNAs with  cDNA at the desired position by PCR as described previously [3]. 
Cell lines Ba/F3 (murine proB cells), BEAS2B (human normal bronchial epithelial cells), 
H3122 (human NSCLC cells with  variant 1), and H2228 (human NSCLC cells 
with  variant 3b) were grown in RPMI 1640 (InvitrogenGIBCO, Grand Island, 
NY, USA) with 10% of fetal bovine serum (FBS), 50 8g/mL penicillin, and 100 8g/mL 
streptomycin at 37°C in a humidified 5% CO2 incubator [46]. The medium for Ba/F3 cells 
was supplemented with IL3 (0.5 ng/mL, Enzo, Farmingdale, NY, USA). To establish stable 
cell lines, Ba/F3 cells were transfected with  variantencoding plasmids using the 
Neon
TM
 Transfection System (MPK5000; Invitrogen). After 48 hours, the medium for the 
cells was replaced with an IL3free medium containing 200 µg/mL hygromycin B (10680
010, Invitrogen) to select EML4ALKexpressing cells. BEAS2B cells were transiently 
transfected with  variants using Lipofectamine 2000 (11668027, Invitrogen). 

 
ALK inhibitors including crizotinib (PF02341066), ceritinib (LDK378), and alectinib 
(CH5424802) were purchased from Selleckchem (Houston, TX). Stock solutions were 
prepared in DMSO. The compounds were diluted with a fresh medium before each 




Wholecell lysates were prepared in RIPA lysis buffer [50 mMTrisHCl (pH 8.0), 150 
mMNaCl, 0.5 mM EDTA, 1 mMdithiothreitol (DTT), 0.1% SDS, 1% NP40] containing a 
protease inhibitor cocktail (BP477; Boston BioProducts, Worcester, MA). Immunoblot 
analyses were carried out with antiphosphoALK (Tyr1604) (3341; Cell Signaling 
Technology, Beverly, MA), antiALK (104809; NOVO, OULU, Finland), and antiβactin 
(A5441; Sigma, St. Louis, MO) antibodies. The blots were visualized using the SuperSignal 
West Pico Chemiluminescent Substrate (34080; Pierce, Rockford, IL).  
 
#	"		 
Cells were seeded in a complete growth medium in 96well plates at 3 × 10
3
 cells per well. 
After 24 hours, the cells were incubated with crizotinib, ceritinib, alectinib, or DMSO in the 
presence of 10% of FBS. After 72 hours of treatment, cell viability was determined using the 
CellTiterGlo
®
 Luminescent Cell Viability Assay (Promega, Madison, WI, USA). The half
maximal inhibitory concentration (IC50) values were calculated from doseresponse curves in 




Cells were lysed with RIPA lysis buffer. Three hundred nanograms of total cell extracts per 
reaction were analyzed using the Universal Tyrosine Kinase Assay Kit (MK410; Takara Bio, 
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